These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 23278995

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
    Valentino LA, Recht M, Dipaola J, Shapiro AD, Pipe SW, Ewing N, Urgo J, Bullock T, Simmons M, Deguzman C.
    Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.
    Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld EJ, Rodriguez N, Wicklund B, Quon D, Aledort L.
    J Thromb Haemost; 2011 Nov; 9(11):2229-34. PubMed ID: 21883884
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Von Willebrand factor-containing factor VIII concentrates and inhibitors in haemophilia A. A critical literature review.
    Franchini M, Lippi G.
    Thromb Haemost; 2010 Nov; 104(5):931-40. PubMed ID: 20838738
    [Abstract] [Full Text] [Related]

  • 33. Inhibitors: our greatest challenge. Can we minimize the incidence?
    Kruse-Jarres R.
    Haemophilia; 2013 Jan; 19 Suppl 1():2-7. PubMed ID: 23278993
    [Abstract] [Full Text] [Related]

  • 34. Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution?
    Di Minno G, Coppola A.
    Haemophilia; 2013 Jan; 19 Suppl 1():18-23. PubMed ID: 23278996
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Successful immune tolerance induction with a plasma-derived FVIII concentrate and intravenous immunoglobulins in a pediatric patient with congenital severe hemophilia A and poor prognostic factors.
    de Cos C, Rodríguez-Martorell J.
    Blood Coagul Fibrinolysis; 2014 Jan; 25(1):77-80. PubMed ID: 24231694
    [Abstract] [Full Text] [Related]

  • 37. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.
    Dimichele D.
    Haemophilia; 2009 Jan; 15(1):320-8. PubMed ID: 18976249
    [Abstract] [Full Text] [Related]

  • 38. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K, Male C, Falger J, Pabinger I.
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [Abstract] [Full Text] [Related]

  • 39. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
    Madoiwa S, Kobayashi E, Kashiwakura Y, Sakata A, Yasumoto A, Ohmori T, Mimuro J, Sakata Y.
    Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
    [Abstract] [Full Text] [Related]

  • 40. The burden of inhibitors in haemophilia patients.
    Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S.
    Thromb Haemost; 2016 Aug 31; 116 Suppl 1():S10-7. PubMed ID: 27528280
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.